Cargando…
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
BACKGROUND: Cutaneous T‐cell lymphomas (CTCL) are rare types of non‐Hodgkin lymphoma, which present in skin. Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes which make up two‐thirds of all CTCL cases. The phase 3 MAVORIC study (NCT01728805) compared mogamulizumab to vorinostat in MF and...
Autores principales: | Beylot‐Barry, Marie, Booken, Nina, Weishaupt, Carsten, Scarisbrick, Julia, Wu, Wende, Rosen, Jan‐Paul, Medley, Michael C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087984/ https://www.ncbi.nlm.nih.gov/pubmed/35993803 http://dx.doi.org/10.1111/jdv.18549 |
Ejemplares similares
-
The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015) -
PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023) -
Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023) -
Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021) -
Mycosis fungoides and Sézary syndrome
por: Lee, Hyewon
Publicado: (2023)